Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 3
2011 3
2012 4
2013 3
2014 5
2015 2
2016 4
2017 9
2018 10
2019 9
2020 13
2021 19
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

80 results
Results by year
Filters applied: . Clear all
Page 1
Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer.
Salazar Y, Zheng X, Brunn D, Raifer H, Picard F, Zhang Y, Winter H, Guenther S, Weigert A, Weigmann B, Dumoutier L, Renauld JC, Waisman A, Schmall A, Tufman A, Fink L, Brüne B, Bopp T, Grimminger F, Seeger W, Pullamsetti SS, Huber M, Savai R. Salazar Y, et al. Among authors: tufman a. J Clin Invest. 2020 Jul 1;130(7):3560-3575. doi: 10.1172/JCI124037. J Clin Invest. 2020. PMID: 32229721 Free PMC article.
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).
Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, De Ruysscher D. Peters S, et al. Among authors: tufman a. J Thorac Oncol. 2021 Feb;16(2):278-288. doi: 10.1016/j.jtho.2020.10.129. Epub 2020 Nov 12. J Thorac Oncol. 2021. PMID: 33188912 Free article. Clinical Trial.
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D. Peters S, et al. Among authors: tufman a. Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3. Lung Cancer. 2019. PMID: 31200833 Clinical Trial.
[Lung cancer].
Huber RM, Tufman A. Huber RM, et al. Among authors: tufman a. Dtsch Med Wochenschr. 2014 Mar;139(11):545-52; quiz 553-6. doi: 10.1055/s-0033-1349593. Epub 2014 Mar 4. Dtsch Med Wochenschr. 2014. PMID: 24595713 Review. German. No abstract available.
Late-onset severe pneumonitis under osimertinib.
Syunyaeva Z, Berghof K, Kauffmann-Guerrero D, Götschke J, Tufman A, Kahnert K. Syunyaeva Z, et al. Among authors: tufman a. AME Case Rep. 2019 Oct 15;3:39. doi: 10.21037/acr.2019.09.01. eCollection 2019. AME Case Rep. 2019. PMID: 31728437 Free PMC article.
Black and Blue.
Kauffmann-Guerrero D, Kahnert K, Pratschke S, Angstwurm M, Tufman A, Huber RM. Kauffmann-Guerrero D, et al. Among authors: tufman a. Respiration. 2017;94(5):465-466. doi: 10.1159/000479703. Epub 2017 Sep 7. Respiration. 2017. PMID: 28877530 Free article. No abstract available.
PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions.
Eze C, Schmidt-Hegemann NS, Sawicki LM, Kirchner J, Roengvoraphoj O, Käsmann L, Mittlmeier LM, Kunz WG, Tufman A, Dinkel J, Ricke J, Belka C, Manapov F, Unterrainer M. Eze C, et al. Among authors: tufman a. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3975-3989. doi: 10.1007/s00259-021-05211-8. Epub 2021 Mar 24. Eur J Nucl Med Mol Imaging. 2021. PMID: 33760957 Free PMC article. Review.
80 results